Prospective Study on the Use of Middle Meningeal Artery Embolization for Chronic Subdural Haematoma
Chronic Subdural Hematoma, Subdural Hematoma
About this trial
This is an interventional treatment trial for Chronic Subdural Hematoma focused on measuring chronic subdural hematoma, subdural hematoma, head injury, middle meningeal artery, hemorrhage, embolization
Eligibility Criteria
Inclusion Criteria:
- Patients (age 18 or above) with chronic subdural haematoma diagnosed by computed tomography and clinical presentation.
Exclusion Criteria:
- SDH with thickness of 10mm or less, lack of mass effect.
- SDH secondary to existing conditions (brain tumour, arachnoid cyst, spontaneous intracranial hypotension, previous craniotomy not due to chronic SDH)
- Patients in poor medication condition or with life expectancy less than 6 months.
Sites / Locations
- Department of Surgery, The Chinese University of Hong Kong
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Embolization Group
Control Group
Patients with residual or recurrent haematoma (higher than 10mm thickness of haematoma at any dimension) following prior surgical evacuation of haematoma will be admitted to the Embolization Group and undergo embolization of MMA. Serial CT scans will be taken at times of presentation of the residual or recurrent haematoma, 1-day, 1-week, 1-month, 3-month, and 6-month following embolization. Size of haematoma will be measured for comparison to the Control Group. Clinical examinations will be done at the same setting.
All symptomatic patients (headache unresponsive to analgesic or neurological deficits including focal neurological deficits, deteriorated consciousness, headache, seizures, and other signs or symptoms suggestive of SDH as the cause) will undergo haematoma evacuation either by burr-hole drainage or craniotomy. Their response to treatment, neurological status, and CT scans will be monitored. Asymptomatic patients will be monitored radiologically (CT) every 2-4 weeks. The decision for surgical evacuation of haematoma will be based on CT findings (increasing haematoma size) and presentation of symptoms or neurological deficits. They remain in the control group should they refuse embolization of MMA. The size of haematoma will be measured continuously based on CT scans taken at times of presentation, 1-day, 1-week, 1-month, 3-month, and 6-month post-op. Size of haematoma, residual or recurrent will be measured for comparison to the Embolization Group.